Table 1.
Patient Characteristics, Overall and Stratified by non-enhancing component.
| Characteristic | Overall n = 183 |
Patients with non-enhancing tumor component < median n = 91 |
Patients with non-enhancing tumor component ≥ median n =92 |
p-value** |
|---|---|---|---|---|
| Age at Diagnosis (years) | 59 (34, 88) | 59 (34, 88) | 59 (39, 79) | 0.8691 |
| Maximum Tumor Dimension (cm) | 5 (1, 17) | 4 (1, 14) | 7 (2, 17) | <0.0001 |
| Gender | ||||
| Female | 62 (34) | 31 (34) | 31 (34) | 0.958 |
| Male | 121 (66) | 60 (66) | 61 (66) | |
| Race | ||||
| white | 176 (96) | 87 (96) | 89 (97) | 0.897 |
| Others | 7 (4) | 4 (4) | 3 (3) | |
| Tumor Grade | ||||
| G1 | 1 (0.5) | 1 (1) | 0 (0) | 0.0589 |
| G2 | 72 (39) | 40 (44) | 32 (35) | |
| G3 | 79 (43) | 41 (45) | 38 (41) | |
| G4 | 31 (17) | 9 (10) | 22 (24) | |
| AJCC Stage | ||||
| Stage I | 96 (53) | 65 (71) | 31 (34) | <0.0001 |
| Stage II | 14 (8) | 2 (2) | 12 (13) | |
| Stage III | 48 (26) | 19 (21) | 29 (32) | |
| Stage IV | 25 (14) | 5 (5) | 20 (22) | |
| Distant Metastasis | ||||
| M0 | 160 (87) | 86 (95) | 74 (80) | 0.0041 |
| M1 | 23 (13) | 5 (5) | 18 (20) | |
| VHL | ||||
| 0 | 71 (39) | 30 (33) | 41 (45) | 0.0776 |
| 1 | 100 (55) | 56 (62) | 44 (48) | |
| NA | 12 (6) | 5 (5) | 7 (8) | |
| PBRM1 | 0.2970 | |||
| 0 | 119 (65) | 63 (69) | 63 (69) | |
| 1 | 52 (28) | 23 (25) | 29 (32) | |
| NA | 12 (7) | 5 (5) | 7 (8) | |
| SETD2 | 0.5960 | |||
| 0 | 157 (86) | 78 (86) | 79 (86) | |
| 1 | 14 (8) | 8 (9) | 6 (7) | |
| NA | 12 (7) | 5 (5) | 7 (8) | |
| BAP1 | 0.6198 | |||
| 0 | 155 (85) | 77 (85) | 78 (85) | |
| 1 | 16 (9) | 5 (5) | 7 (8) | |
| NA | 12 (7) | 9 (10) | 7 (8) | |
| KDM5C | 0.3014 | |||
| 0 | 163 (89) | 80 (88) | 83 (90) | |
| 1 | 8 (4) | 5 (5) | 7 (8) | |
| NA | 12 (7) | 6 (7) | 2 (2) |
*
N (%) for categorical variables; Median (range) for continuous variables
**
P-values are from Wilcoxon rank-sum test for continuous characteristics and Fisher’s exact test for categorical characteristics.